Biomarker may predict which HER2-negative breast cancer patients will benefit from ta
A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond - and which should switch to...
More... |
All times are GMT -7. The time now is 04:36 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021